Myelodysplastic syndrome in the new millennium. How to classify and treat patients?;Myelodysplastický syndrom v novém tisíciletí. Jak klasifikovat a jak léčit nemocné?

Vnitrni Lekarstvi

Volumn 51, Issue 1, 2005, Pages 20-30

  Čermák, Jaroslav ^a   Vitek A ^a   Michalova K ^a,b   Brezinova J ^a   Zemanova Z ^b  

^a INSTITUTE OF HEMATOLOGY AND BLOOD TRANSFUSION   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Classification; Karyotype; Myelodysplastic syndrome; Prognosis; Transplantation; Treatment

Indexed keywords

ARTICLE; CHROMOSOME 5Q; CHROMOSOME DELETION 5; CYTOGENETICS; DISEASE CLASSIFICATION; FLUORESCENCE IN SITU HYBRIDIZATION; HIGH RISK PATIENT; HUMAN; KARYOTYPE; MAJOR CLINICAL STUDY; MYELODYSPLASTIC SYNDROME; PRACTICE GUIDELINE; PROGNOSIS; RETROSPECTIVE STUDY; STEM CELL TRANSPLANTATION; SURVIVAL; WORLD HEALTH ORGANIZATION;

EID: 20344399657     PISSN: 0042773X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Anderson JE Bone marrow transplantation for myelodysplasia. Blood Reviews 2000; 14: 63-77.
2. Bennett JM, Catovsky D, Daniel MT et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982; 51: 189-199.
3. Cox DR. Regression models and life-tables. J R Stat Soc 1972; 34: 187.
4. Cutler C, Lee S, Greenberg P et al. A decision analysis of allogeneic stem cell transplantation for MDS: Delayed transplantation for low risk MDS is associated with improved outcome. Blood 2002; 100: 74a.
5. Čermák J. Myelodysplastický syndrom. In: Mayer J, Starý J. Leukémie. Praha. Grada 2002: 221-234.
6. De Witte T, Zwaan F, Hermans J et al. Allogeneic bone marrow transplantation for secondary leukemia and myelodysplastic syndrome:a survey by the Leukemia Working Party of the European Bone marrow Transplantation Group (EBMTG). Br J Haematol 1990; 74: 151-155.
7. De Witte T, Suciu S, Verhoef G et al. Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukemia following MDS. Blood 2002; 98: 2326-2331.
8. Germing U, Gattermann N, Strupp C et al. Validation of the WHO proposals for a new classification of primary myelodysplastic syndromes: a retrospective analysis of 1600 patients. Leuk Res 2000; 24: 983-992.
9. Greenberg P, Cox C, Le Beau MM et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89: 2079-2088.
10. Harris NL, Jaffe ES, Diebold J et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee Meeting - Airlie House, Virginia, November 1997. J Clin Oncol 1999; 17: 3835-3849.
11. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
12. Parker JE, Shafi T, Pagliuca A et al. Allogeneic stem cell transplantation in the myelodysplastic syndromes: interim results of outcome following reduced-intensity conditioning compared with standard preparative regimens. Br J Haematol 2002; 119: 144-154.
13. Raza A, Gregory A, Preisler HD. The myelodysplastic syndromes in 1996: complex stem cell disorders confounded by dual actions of cytokines. Leukemia Res 1996; 20: 881-890.
14. Sierra J, Pérez WS, Rozman C et al. Bone marrow transplantation from HLA-identical siblings as treatment for myelodysplasia. Blood 2002; 100: 1997-2004.
15. Steensma DP, Tefferi A The myelodysplastic syndrome(s): a perspective and review highlighting current controversies. Leuk Res 2003; 27: 95-120.
16. Sutton L, Chastang C, Ribaud P et al. Factors influencing outcome in de novo myelodysplastic syndromes treated by allogeneic bone marrow transplantation: a long term study of 71 patients. Blood 1996; 88: 358-365.
17. Van Den Berghe H, Cassiman JJ, David G et al. Distinct hematological disorder with deletion of long arm of No. 5 chromosome. Nature 1974; 251: 437.
18. Wijermans P, Lubbert M, Verhoef G et al. Low-dose 5-Aza-2,-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. J Clin Oncol 2000; 18: 956-962.